title: Effect of losartan and benzbromarone on the level of human urate transporter 1 mRNA.
abstract: Both an angiotensin II receptor blocker, losartan (CAS 124750-99-8) and a serum urate lowering agent, benzbromarone (CAS 3562-84-3) exert a uricosuric action by inhibiting urate transporter 1 (URAT1). A recent clinical trial indicated that losartan could reduce the level of serum urate in hypertensive patients treated with urate lowering agents, suggesting the different mode of action of losartan from benzbromarone. In the present study, the effect of losartan and benzbromarone on the level of URAT1 mRNA was determined in transfected HEK293 cells. Losartan caused a significant reduction of its mRNA level, whereas it was not affected by benzbromarone. These results indicate that losartan decreases the level of human URAT1 mRNA, which may underlie the uricosuric action of losartan in hypertensive patients treated with serum urate lowering agents.
authors.affiliation: Division of Regenerative Medicine and Therapeutics, Department of Genetic Medicine and Regenerative Therapeutics, Institute of Regenerative Medicine and Biofunction, Tottori University Graduate School of Medical Science, Yonago, Japan.
authors.forename: Yora
authors.initials: Y
authors.lastname: Nindita
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Hamada
authors.forename: Udin
authors.initials: U
authors.lastname: Bahrudin
authors.forename: Makoto
authors.initials: M
authors.lastname: Hosoyamada
authors.forename: Kimiyoshi
authors.initials: K
authors.lastname: Ichida
authors.forename: Chisato
authors.initials: C
authors.lastname: Iwai
authors.forename: Sunao
authors.initials: S
authors.lastname: Urashima
authors.forename: Masanari
authors.initials: M
authors.lastname: Kuwabara
authors.forename: Narimasa
authors.initials: N
authors.lastname: Kuwabara
authors.forename: Sulistiyati Bayu
authors.initials: SB
authors.lastname: Utami
authors.forename: Einosuke
authors.initials: E
authors.lastname: Mizuta
authors.forename: Kensaku
authors.initials: K
authors.lastname: Yamada
authors.forename: Osamu
authors.initials: O
authors.lastname: Igawa
authors.forename: Chiaki
authors.initials: C
authors.lastname: Shigemasa
authors.forename: Haruaki
authors.initials: H
authors.lastname: Ninomiya
authors.forename: Takuya
authors.initials: T
authors.lastname: Tsuchihashi
authors.forename: Ichiro
authors.initials: I
authors.lastname: Hisatome
mesh_terms: D047228:Angiotensin II Type 1 Receptor Blockers / Q000494:pharmacology*; D001553:Benzbromarone / Q000494:pharmacology*; D002460:Cell Line; D006801:Humans; D007668:Kidney / Q000378:metabolism; D019808:Losartan / Q000494:pharmacology*; D027361:Organic Anion Transporters / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D027701:Organic Cation Transport Proteins / Q000037:antagonists & inhibitors / Q000096:biosynthesis*; D012333:RNA, Messenger / Q000096:biosynthesis*; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014527:Uric Acid / Q000378:metabolism; D014528:Uricosuric Agents / Q000494:pharmacology*
chemical_list: D047228:Angiotensin II Type 1 Receptor Blockers; D027361:Organic Anion Transporters; D027701:Organic Cation Transport Proteins; D012333:RNA, Messenger; C491241:SLC22A12 protein, human; D014528:Uricosuric Agents; D014527:Uric Acid; D001553:Benzbromarone; D019808:Losartan